The global emergence of novel coronavirus disease 2019 (COVID-19) has underlined the requirement for rapid assays with high sensitivity and specificity for detection of infection and further to understand the molecular complexity of the disease.
Explore how our customers have used the Evosep One to develop an effective screening assay and comprehensive understanding of the disease.
the current situation for clinical proteomics
Professor Akhilesh Pandey now from the Mayo Clinic, Rochester, US talks with Nicolai Bache, Head of Applications at Evosep about the current situation for clinical proteomics and what is looming on the horizon.
With the ongoing COVID-19 pandemic the need for robust solutions for clinical proteomics are urgently required.
STANDARDIZATION IS KEY
The Evosep One serves as a robust and standardized front-end solution, which can be paired with the most widely used mass spectrometers. It allows for up to 300 samples analyzed per day and is therefore ideally suited for testing a large sample cohort with a specific clinical assay.
SENSITIVE AND SPECIFIC TARGETED ASSAY FOR DETECTION OF COVID-19
This publication describes the development of an automated antibody capture-based workflow coupled to a targeted FAIMS-PRM assay on an Orbitrap Exploris 480 MS developed by the Akhilesh Pandey group at the Mayo Clinic, Rochester, US from the analysis of more than 700 nasopharyngeal swab samples were analyzed.
The key advantage of the assay, which allows for 200 samples analyzed per day, is the high specificity and comparable sensitivity to the gold standard RT-PCR method for the diagnosis of SARS-CoV-2. The method can be adapted for detection of novel variants of SARS-CoV-2 as they appear and can easily be deployed at routine clinical laboratories with mass spectrometry instrumentation.
COMPREHENSIVE MULTI-OMICS UNDERSTANDING OF COVID-19
This publication from multiple research groups in Germany describes the molecular functions of viral proteins and their interactions with the host proteome of SARS-CoV-2. It serves as a resource describing the interplay between different omics levels.
The impact of viral infection on the proteome and phosphoproteome were analyzed in a time-resolved manner using the Evosep One with data-independent analysis on a Q Exactive HF-X. The analysis revealed key pathways perturbed during the infection identifying potential vulnerable points of SARS-CoV-2 that could be targeted by well-characterized selective drugs for antiviral therapies.
SERUM PROTEOMICS AND ANALYSIS OF RED BLOOD CELLS FROM COVID-19 PATIENTS
In these two studies, researchers from University of Colorado performed proteomics analysis of Covid-19 patients and healthy control individuals.
By using the Evosep One coupled to a timsTOF Pro, they measured the proteomes of red blood cells (RBC) and identified increased glycolysis in RBCs from COVID-19 patients, accompanied by increased oxidation of key structural proteins.
They also did a serum proteomics analysis stratified by the degree of inflammation, represented by IL-6 levels as a marker of disease severity. Their results highlight a clear increase in the levels of inhibitory components of the fibrinolytic cascade in severe COVID-19 disease, providing potential clues related to the etiology of coagulopathic complications in COVID-19 and paving the way for potential therapeutic interventions, such as the use of pro-fibrinolytic agents.
find all publications, product brochures and presentations with Evosep One
The five STANDARD METHODS
For the Evosep One
HOW FAR WILL YOU GO?
More research on COVID-19
Here you can see publications available on COVID-19 featuring Evosep One. For a full overview of publications published using the Evosep One Technology visit our Literature room here
|Title||Subject||Material||Year||Summary||Institute||Evosep method||MS instrumentation||Learn More|
|Serum Proteomics in COVID-19 Patients: Altered Coagulation and Complement Status as a Function of IL-6 Level||Clinical research, Covid-19, DDA, Serum||Publication||2020||This publication describes a serum proteomics analysis of COVID-19 patients, stratified by the degree of inflammation, represented by IL-6 levels. It highlights an increase in the levels of inhibitory components of the fibrinolytic cascade in severe COVID-19 disease, providing potential therapeutic interventions, such as the use of pro-fibrinolytic agents.||University of Colorado, US||Bruker timsTOF Pro|
|Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV||Clinical research, Covid-19, DIA, PTM||Publication||2020||This publication describes the molecular functions of viral proteins and their interactions with the host proteome of SARS-CoV-2. The impact of viral infection on the proteome and phosphoproteome were analyzed in a time-resolved manner by DIA. The analysis revealed key pathways perturbed during the infection identifying potential vulnerable points of SARS-CoV-2.||Max Planck Institute of Biochemistry, Martinsried, Germany||30 SPD, 60 SPD||Thermo Q Exactive HF-X|
|Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens||Clinical research, Covid-19, DDA, Targeted workflow||Publication||2020||This publication by the Akhilesh Pandey group describes a targeted FAIMS-PRM assay on an Orbitrap Exploris 480 MS. More than 700 nasopharyngeal swab samples were analyzed with high specificity and comparable sensitivity to the gold standard RT-PCR method for the diagnosis of SARS-CoV-2.||Mayo Clinic Rochester, United States||100 SPD, 200 SPD||Thermo Orbitrap Exploris 480|
|Evidence of Structural Protein Damage and Membrane Lipid Remodeling in Red Blood Cells from COVID-19 Patients||Clinical research, Covid-19, DDA||Publication||2020||In this study, researchers from University of Colorado led by Angelo D’Alessandro, performed proteomics analysis of Covid-19 patients and healthy control individuals. They measured the proteomes of red blood cells (RBC) and identified increased glycolysis in RBCs from COVID-19 patients, accompanied by increased oxidation of key structural proteins.||University of Colorado, United States||Bruker timsTOF Pro|
|Seroconversion stages COVID19 into distinct pathophysiological states||Clinical research, Covid-19, Plasma||Publication||2020||In this study, researchers from University of Colorado led by Joaquin M. Espinosa, found highly variable seroconversion status among hospitalized Covid-19 patients. Their results support the existence of distinct pathophysiological states, with seroconversion status being potentially useful as a surrogate marker of underlying processes.||University of Colorado, United States.||30 SPD||Bruker timsTOF Pro|
|Fluvastatin mitigates SARS-CoV-2 infection in human lung cells||Clinical research, Covid-19||Publication||2020||Clinical data of patients suffering from COVID-19 have indicated that statin therapy, used to treat high cholesterol, is associated with a better clinical outcome. A collaboration led by Gisa Gerold investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that fluvastatin inhibited coronavirus infection, while other tested statins did not.||Medical School Hannover, Germany. Helmholtz Centre for Infection Research, Germany. University of Veterinary Medicine Hannover, Germany. Umeå University, Sweden. German Centre for Infection Research (DZIF), Germany.||Extended method||Bruker timsTOF Pro|
We’d love to hear from you!
Need more information, do not hesitate to contact us.